ArticlePLoS pathogens2020
Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses.
Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Mpox animal models: a comprehensive evaluation of susceptible species for pathogenesis studies and drug discovery.Emerging microbes & infections · 2026Review
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Antiviral innate immunity and adaptive immune responses against monkeypox and viral immune evasion.World journal of virology · 2026Review
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- From skin lesions to multi-organ involvement: Organ tropism and pathogenesis of mpox virus.iScience · 2025Review
- Comparative pathogenicity of vaccinia virus and mpox virus infections in CAST/EiJ mice: Exploring splenomegaly and transcriptomic profiles.Animal models and experimental medicine · 2025Article
- Evaluation of Poxvirus-Specific Antibody Response in Monkey Poxvirus-Negative and -Positive Cohorts.Vaccines · 2025Article
- Poxvirus structural biology for application to vaccine design.Trends in immunology · 2025Review
- Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates.Nature communications · 2025Article
- MPXV infection activates cGAS-STING signaling and IFN-I treatment reduces pathogenicity of mpox in CAST/EiJ mice and rhesus macaques.Cell reports. Medicine · 2025Article
- Monkeypox Virus and Pregnancy.Journal of medical virology · 2025Review
- Inhibition of TIGIT on NK cells improves their cytotoxicity and HIV reservoir eradication potential.mBio · 2025Article
- Monoclonal Antibodies in Light of Mpox Outbreak: Current Research, Therapeutic Targets, and Animal Models.Antibodies (Basel, Switzerland) · 2025Review
- Establishment of an animal model for monkeypox virus infection in dormice.Scientific reports · 2025Article
- Decoding and Unravelling Mpox, Herpes, and Syphilis Infections: A State of Art Review.Current pharmaceutical biotechnology · 2025Review
- Antigen recognition and immune response to monkeypox virus infection: implications for Mpox vaccine design - a narrative review.Le infezioni in medicina · 2025Review
- Mpox mRNA-1769 vaccine inhibits orthopoxvirus replication at intranasal, intrarectal, and cutaneous sites of inoculation.NPJ vaccines · 2024Article
- Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in bothmSphere · 2024Article
- Navigating monkeypox: identifying risks and implementing solutions.Open veterinary journal · 2024Review
- Immune Reconstitution Inflammatory Syndrome Related to Antiretroviral Therapy Initiation in People With HIV and Mpox: An Observational Retrospective Study.Open forum infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The wild-derived inbred CAST/EiJ mouse, one of eight founder strains in the Collaborative Cross panel, is an exceptional model for studying monkeypox virus (MPXV), an emerging human pathogen, and other orthopoxviruses including vaccinia virus (VACV). Previous studies suggested that the extreme susceptibility of the CAST mouse to orthopoxviruses is due to an insufficient innate immune response. Here, we focused on the low number of natural killer (NK) cells in the naïve CAST mouse as a contributing factor to this condition. Administration of IL-15 to CAST mice transiently increased NK and CD8+ T cells that could express IFN-γ, indicating that the progenitor cells were capable of responding to cytokines. However, the number of NK cells rapidly declined indicating a defect in their homeostasis. Furthermore, IL-15-treated mice were protected from an otherwise lethal challenge with VACV or MPXV. IL-15 decreased virus spread and delayed death even when CD4+/CD8+ T cells were depleted with antibody, supporting an early protective role of the expanded NK cells. Purified splenic NK cells from CAST mice proliferated in vitro in response to IL-15 and could be activated with IL-12/IL-18 to secrete interferon-γ. Passive transfer of non-activated or activated CAST NK cells reduced VACV spread but only the latter completely prevented death at the virus dose used. Moreover, antibodies to interferon-γ abrogated the protection by activated NK cells. Thus, the inherent susceptibility of CAST mice to orthopoxviruses can be explained by a low level of NK cells and this vulnerability can be overcome either by expanding their NK cells in vivo with IL-15 or by passive transfer of purified NK cells that were expanded and activated in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.